Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065745 | 0.86 | MTNR1A (0.68) | MTNR1APTPN1NQO2 | |
| SCHEMBL6495378 | 0.84 | MTNR1A (0.67) | MTNR1APTPN1MTNR1B | |
| SCHEMBL1567114 | 0.83 | MTNR1A (0.73) | MTNR1APTPN1NQO2TRPV1MTNR1B | |
| SCHEMBL919206 | 0.83 | MTNR1A (0.64) | MTNR1APTPN1HPGDMTNR1BMEN1 | |
| SCHEMBL919204 | 0.83 | MTNR1A (0.64) | MTNR1APTPN1HPGDMTNR1BMEN1 | |
| SCHEMBL761446 | 0.82 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL5511489 | 0.82 | MTNR1A (1.00) | MTNR1ANQO2TRPV1MTNR1BMEN1 | |
| SCHEMBL29941181 | 0.82 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL9128038 | 0.82 | MTNR1A (0.63) | MTNR1APTPN1NQO2HPGDMTNR1B | |
| SCHEMBL8858549 | 0.81 | MTNR1A (0.61) | MTNR1APTPN1HPGDTRPV1MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806346-B1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MTNR1A 1715/4885PTPN1 3163/4885NQO2 721/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MTNR1A 1937/4885PTPN1 2979/4885NQO2 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.